| Literature DB >> 28915609 |
Chang Zheng1,2, Xuelian Li1,2, Lingzi Xia1,2, Xue Fang1,2, Xiaowei Quan1,2, Zhihua Yin1,2, Yuxia Zhao3, Baosen Zhou1,2.
Abstract
Occurrence and development of non-small cell lung cancer (NSCLC) is a complex process affected both by gene and environment. Single nucleotide polymorphisms (SNPs) in microRNAs' (miRNAs) biogenesis influenced the expression of mature miRNAs, further had an impact on risk of NSCLC. Our study focused on the correlation between rs213210, rs421446 or rs107822 polymorphisms in pri-miR-219-1 and susceptibility or prognosis of NSCLC in Chinese. A case-control study of 405 new-diagnosis patients and 405 controls was performed. Ten ml venous blood from each subject was collected for genotype test via using TaqMan allelic discrimination methodology and SPSS was performed for statistical analyses. We found that CC genotype in rs213210 (OR=3.462, 95%CI=2.222-5.394, P<0.001) compared with TT genotype and GG genotype in rs107822 (OR=3.553, 95%CI=2.329-5.419, P<0.001) compared with AA genotype showed significantly increased risk of NSCLC. Haplotype analysis showed that pri-miR-219-1 haplotype Crs213210Crs421446Grs107822 was a dangerous haplotype for lung cancer. And polymorphisms in pri-miR-219-1 have showed no relationship with overall survival of NSCLC. Overall, these findings firstly showed that rs213210 and rs107822 could be meaningful as genetic markers for lung cancer risk.Entities:
Keywords: NSCLC; SNP; miRNA; prognosis; susceptibility
Year: 2017 PMID: 28915609 PMCID: PMC5593580 DOI: 10.18632/oncotarget.17035
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Demographics of NSCLC patients and controls
| Cases | Controls | |||
|---|---|---|---|---|
| Gender | male | 256(64.6) | 140(35.4) | |
| female | 149(36.0) | 265(64.0) | <0.001 | |
| Age(years) | mean±SD | 51.27±22.08 | 50.23±21.02 | 0.49 |
| Smoke | never | 310(76.5) | 357(88.1) | |
| yes | 95(23.4) | 48(11.9) | <0.001 | |
| Histology | ADC | 261(80.5) | ||
| SCC | 69(21.3) | |||
| LCC | 10(3.1) | |||
| unknown | 65(20.1) | |||
| Chemo | no | 6(1.8) | ||
| yes | 297(91.7) | |||
| unknown | 21(6.5) | |||
| Surgical | No | 90(27.8) | ||
| yes | 226(69.7) | |||
| unknown | 8(2.5) | |||
| Clinic stage | IA+IB | 128(40.5) | ||
| IIA+IIB | 77(24.8) | |||
| IIIC+IIID | 58(17.9) | |||
| IV | 61(18.8) | |||
| Time(months) | mean±SD | 24.35±18.70 | ||
| Status | alive | 65(20.0) | ||
| dead | 259(80.0) |
Distribution of pri-miR-219-1 rs213210, rs421446 and rs107822 genotypes and ORs for NSCLC cases and controls
| Genotype | Cases | Controls | OR | 95%CI | OR adj | 95%CI adj | ||
|---|---|---|---|---|---|---|---|---|
| rs213210 | ||||||||
| TT | 113 | 160 | <0.001 | <0.001 | ||||
| CT | 194 | 191 | 0.023 | 1.438 | (1.052, 1.967) | 0.057 | 1.383 | (0.990, 1.932) |
| CC | 98 | 54 | <0.001 | 2.570 | (1.705, 3.873) | <0.001 | 3.462 | (2.222, 5.394) |
| TT | 113 | 160 | ||||||
| CT+CC | 292 | 245 | 0.001 | 1.688 | (1.257, 2.266) | <0.001 | 1.779 | (1.301, 2.432) |
| TT+CT | 307 | 351 | ||||||
| CC | 98 | 54 | <0.001 | 2.075 | (1.439, 2.991) | <0.001 | 2.874 | (1.930, 4.279) |
| T allele | 420 | 511 | ||||||
| C allele | 390 | 299 | <0.001 | 1.587 | (1.301,1.935) | <0.001 | 1.792 | (1.449, 2.216) |
| rs421446 | ||||||||
| CC | 129 | 174 | 0.004 | 0.040 | ||||
| TC | 198 | 170 | 0.004 | 1.571 | (1.156, 2.134) | 0.017 | 1.485 | (1.075, 2.051) |
| TT | 78 | 61 | 0.008 | 1.725 | (1.150, 2.586) | 0.079 | 1.469 | (0.956, 2.258) |
| CC | 129 | 174 | ||||||
| CT+TT | 276 | 231 | 0.001 | 1.602 | (1.202, 2.136) | 0.522 | 0.920 | (0.712, 1.188) |
| CC+CT | 327 | 344 | ||||||
| TT | 78 | 61 | 0.165 | 1.295 | (0.899, 1.865) | 0.012 | 1.475 | (1.089, 1.997) |
| C allele | 456 | 518 | ||||||
| T allele | 354 | 292 | 0.002 | 1.377 | (1.128,1.681) | 0.026 | 1.272 | (1.030, 1.572) |
| rs107822 | ||||||||
| AA | 79 | 162 | <0.001 | <0.001 | ||||
| GA | 206 | 174 | <0.001 | 2.428 | (1.735, 3.398) | <0.001 | 2.376 | (1.664, 3.392) |
| GG | 120 | 69 | <0.001 | 3.566 | (2.391, 5.320) | <0.001 | 3.553 | (2.329, 5.419) |
| AA | 79 | 162 | ||||||
| GA+GG | 326 | 243 | <0.001 | 2.751 | (2.005, 3.774) | <0.001 | 2.711 | (1.941, 3.788) |
| AA+GA | 285 | 336 | ||||||
| GG | 120 | 69 | <0.001 | 2.050 | (1.466, 2.868) | <0.001 | 2.074 | (1.455, 2.957) |
| G allele | 446 | 312 | ||||||
| A allele | 364 | 498 | <0.001 | 4.026 | (3.251, 4.985) | <0.001 | 1.952 | (1.582, 2.407) |
Padj is adjusted by smoking, age and gender.
Interaction of pri-miR-219-1 variants and tobacco exposure on NSCLC
| Genotype | Smoking | Cases | Controls | OR(95% CI) | OR(95% CI) adj. | ||
|---|---|---|---|---|---|---|---|
| rs213210 | |||||||
| TT | - | 88 | 138 | <0.001 | <0.001 | ||
| CT | - | 140 | 173 | 0.180 | 1.27(0.90, 1.80) | 0.199 | 1.27(0.88, 1.84) |
| CC | - | 82 | 46 | <0.001 | 2.80(1.78, 4.38) | <0.001 | 3.83(2.37, 6.20) |
| TT | + | 25 | 22 | 0.073 | 1.78(0.95, 3.35) | 0.009 | 2.45(1.25, 4.81) |
| CT | + | 54 | 18 | <0.001 | 4.71(2.59, 8.54) | <0.001 | 5.15(2.74, 9.67) |
| CC | + | 16 | 8 | 0.012 | 3.14(1.29, 7.64) | 0.002 | 4.33(1.70, 11.06) |
| rs421446 | |||||||
| CC | - | 109 | 150 | <0.001 | <0.001 | ||
| TC | - | 148 | 154 | 0.101 | 1.32(0.95, 1.85) | 0.179 | 1.27(0.90, 1.80) |
| TT | - | 53 | 53 | 0.168 | 1.38(0.87, 2.17) | 0.358 | 1.25(0.78, 2.01) |
| CC | + | 20 | 24 | 0.676 | 1.15(0.60, 2.18) | 0.453 | 1.30(0.66, 2.55) |
| TC | + | 50 | 16 | <0.001 | 4.30(2.33, 7.95) | <0.001 | 4.65(2.45, 8.82) |
| TT | + | 25 | 8 | 0.001 | 4.30(1.87, 9.90) | 0.001 | 4.30(1.81, 10.24) |
| rs107822 | |||||||
| AA | - | 65 | 147 | <0.001 | <0.001 | ||
| GA | - | 151 | 151 | <0.001 | 2.26(1.56, 3.27) | <0.001 | 2.32(1.58, 3.42) |
| GG | - | 94 | 59 | <0.001 | 3.60(2.33, 5.58) | <0.001 | 3.64(2.30, 5.75) |
| AA | + | 14 | 15 | 0.062 | 2.11(0.96, 4.63) | 0.050 | 2.28(1.00, 5.22) |
| GA | + | 55 | 23 | <0.001 | 5.41(3.07, 9.54) | <0.001 | 6.06(3.33, 11.03) |
| GG | + | 26 | 10 | <0.001 | 5.88(2.68, 12.90) | <0.001 | 7.24(3.19, 16.44) |
P-value adj. is adjusted by age and gender.
Figure 1Distribution of haplotypes in cases and controls
(1) The area of the pie represents the odd ratio (take the inverse when OR < 1). (2) Red pies present dangerous type, the blue ones are protectors, grey pie means no statistical significance different. (3) The axis represents the number of subjects.
Association analysis of rs213210, rs421446 and rs107822 on the pri-miR-219-1 with risk of NSCLC
| Haplotype | Cases (%) | Controls (%) | OR (95%CI) | |
|---|---|---|---|---|
| C C A | 73 (9.0) | 145(17.9) | <0.001 | 0.456 (0.338, 0.615) |
| C C G | 177(21.9) | 43(5.3) | <0.001 | 4.997 (3.524, 7.086) |
| C T A | 70(8.7) | 80(9.9) | 0.403 | 0.867 (0.620, 1.212) |
| C T G | 68(8.5) | 30(3.7) | <0.001 | 2.379 (1.533, 3.693) |
| T C A | 83(10.4) | 274(33.9) | <0.001 | 0.225 (0.172, 0.295) |
| T C G | 121(15.0) | 54(6.8) | <0.001 | 2.419 (1.730, 3.382) |
| T T A | 135(16.8) | 120(14.9) | 0.291 | 1.155 (0.884, 1.509) |
| T T G | 78(9.7) | 60(7.5) | 0.109 | 1.330 (0.937, 1.887) |
pri-miR-219-1 SNPs associated with outcomes of NSCLC patients and stratified by stages
| Genotype | Cases | HR | 95%CI | HR adj | 95%CI adj | ||
|---|---|---|---|---|---|---|---|
| rs213210 | |||||||
| TT | 85 | 0.235 | 0.154 | ||||
| CT | 148 | 0.093 | 1.298 | (0.957, 1.760) | 0.063 | 1.344 | (0.984, 1.836) |
| CC | 91 | 0.224 | 1.236 | (0.879, 1.737) | 0.120 | 1.330 | (0.928, 1.905) |
| Stage I+II | |||||||
| T allele | 206 | ||||||
| C allele | 204 | 0.114 | 0.838 | (0.673, 1.043) | 0.184 | 0.860 | (0.678, 1.075) |
| Stage III+IV | |||||||
| T allele | 112 | ||||||
| C allele | 126 | 0.047 | 1.365 | (1.004, 1.855) | 0.065 | 1.358 | (0.981, 1.878) |
| rs421446 | |||||||
| CC | 110 | 0.358 | 0.413 | ||||
| TC | 151 | 0.152 | 0.818 | (0.622, 1.077) | 0.185 | 0.829 | (0.627, 1.094) |
| TT | 63 | 0.477 | 0.880 | (0.617, 1.253) | 0.482 | 0.878 | (0.611, 1.261) |
| Stage I+II | |||||||
| C allele | 235 | ||||||
| T allele | 175 | 0.310 | 0.892 | (0.714, 1.113) | 0.199 | 0.864 | (0.692, 1.080) |
| Stage III+IV | |||||||
| C allele | 136 | ||||||
| T allele | 102 | 0.102 | 0.775 | (0.572, 1.051) | 0.147 | 0.795 | (0.582, 1.084) |
| rs107822 | |||||||
| AA | 66 | 0.147 | 0.139 | ||||
| GA | 159 | 0.693 | 1.066 | (0.776, 1.465) | 0.536 | 1.107 | (0.803, 1.526) |
| GG | 99 | 0.084 | 1.355 | (0.960, 1.913) | 0.065 | 1.384 | (0.980, 1.955) |
| Stage I+II | |||||||
| A allele | 192 | ||||||
| G allele | 217 | 0.054 | 1.243 | (0.996, 1.552) | 0.057 | 1.241 | (0.994, 1.549) |
| Stage III+IV | |||||||
| A allele | 99 | ||||||
| G allele | 140 | 0.895 | 0.980 | (0.724, 1.326) | 0.930 | 0.987 | (0.729, 1.336) |
Padj is adjusted by smoking, age and gender.